Guardant Health, IPS Genomix Collaborate
News Sep 20, 2016
Guardant Health has announced that it has inked an agreement with IPS Genomix to make its Guardant360 liquid biopsy test available to oncologists and their patients in the Middle East. Guardant Health Co-founder and CEO Helmy Eltoukhy said in a statement that the distribution deal grants patients across the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman, Lebanon, Egypt, and Jordan access to the targeted sequencing-based assay.
Guardant360 analyzes DNA fragments shed from solid tumors into the blood of cancer patients, in order to detect various classes of somatic genomic alterations in 70 genes with relevance to specific targeted therapies, or other aspects of clinical cancer management.
Under the terms of the new agreement, IPS Genomix will facilitate patient access to Guardant360, and will handle distribution and reimbursement for the test in the region. Guardant Health will still perform all sequencing, computation, and other analyses at its CLIA lab in Redwood City, California.
Guardant signed another similar international distribution deal with Teva Pharmaceuticals subsidiary Oncotest-Teva earlier this year, making Guardant360 available to patients with advanced cancer in Israel.
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.